What is NexGel's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for NexGel year over year?

What were the key takeaways from NexGel’s earnings call?

What is the market's earnings forecast for NexGel next quarter?

What were the key takeaways from NexGel's earnings call?

Did NexGel beat or miss consensus estimates last quarter?

What guidance did NexGel's management provide for the next earnings period?

What factors drove the changes in NexGel's revenue and profit?

- **Revenue Stability with Margin Improvement**: Q3 revenue flat at $2.9 million, but gross margin rose to 42.4%, narrowing EBITDA loss to $354,000.
- **Contract Manufacturing Momentum**: New partnerships with iRhythm and Cintas drive $907,000 in Q3 revenue, with Q4 orders expected to boost growth.
- **Consumer Product Recovery**: Logistical delays resolved; Q4 launches of lip gloss, Kenkoderm eczema line, and STADA's Glutacin aim for holiday sales surge.
- **STADA Financing Boost**: $1 million from STADA supports product launches, with Q4 soft launch of Glutacin and full 2026 rollout.
- **Uncertainty with AbbVie**: Concerns over AbbVie's device launch amid impairment charges, highlighting external risks.
- **Q4 Outlook**: Record quarter expected, with full year guidance of $12-12.5 million and EBITDA near breakeven.

**【CEO Summary Section】**
- **Revenue Performance**: Q3 2025 revenue of $2.9 million, flat year-over-year and sequentially, with gross profit margin improving to 42.4% (up from 39.3% in Q3 2024).
- **Contract Manufacturing Growth**: Revenue of $907,000, driven by partnerships with Cintas (SilverSeal wound care kits) and iRhythm (Zio heart monitor integration), with new orders expected this quarter.
- **Consumer Products Expansion**: Despite logistical delays delaying lip gloss launch to late September, Q4 is expected to be strong with new product launches, including Glutacin (STADA partnership) and Kenkoderm's eczema line.
- **STADA Partnership**: $1 million non-dilutive financing secured for product launches, with Q4 soft launch of Glutacin and full launch in January 2026.
- **Financial Outlook**: Full year 2025 guidance of $12-12.5 million revenue, with Q4 expected to be a record quarter and adjusted EBITDA nearing breakeven.

**【CFO Financial Commentary】**
- **Revenue and Costs**: Q3 2025 revenue $2.9 million (flat YoY), cost of revenues $1.7 million (down 5.2% YoY), gross profit $1.24 million (up 6.9% YoY).
- **Profitability Metrics**: Adjusted EBITDA loss narrowed to $354,000 (from $500,000 in Q1 2025), net loss $653,000, and cash balance of $938,000 (plus $920,000 restricted cash from STADA).
- **Expense Management**: Selling, general, and administrative expenses $1.96 million (slight increase YoY due to compensation and consulting fees).

**【Q&A Key Highlights】**
- **Logistical Delays**: Impact of $100-200,000 on Q3 sales resolved, with strong Q4 consumer product performance expected.
- **Guidance Confidence**: Q4 growth driven by new contract manufacturing customers (e.g., iRhythm) and holiday consumer sales, despite potential economic uncertainty.
- **AbbVie Uncertainty**: Concerns over AbbVie's impairment charge and unclear launch timeline for the RESONIC device.
- **Cash Position**: Sufficient liquidity to fulfill orders, with inventory built for Q4 shipments.
- **EBITDA Breakeven**: Potential for adjusted EBITDA breakeven in Q4, contingent on consumer product performance.


NEXGEL, Inc. (NXGL) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 2025 revenue up 100% YoY to $2.9 million, with contract manufacturing and consumer products each growing over 95% YoY.
- **Gross Margin Leap**: 43.6% gross margin vs. 20.3% in Q2 2024, driven by scale and high-margin products.
- **STADA Funding**: $1 million non-dilutive investment to support 9 new digestive enzyme launches, targeting larger markets than histamine sensitivity.
- **Silly George Momentum**: Q2 sales up 95% YoY, with new Focus Packs and lip gloss shades set to boost Q3/Q4 growth.
- **AbbVie Delay**: Medical device launch pushed to Q1 2026, but remains a key long-term opportunity.

**【CEO Opening Remarks】**
- Q2 2025 revenue reached $2.9 million, up 100% YoY, driven by contract manufacturing (103% YoY growth) and consumer products (95% YoY growth). Gross margin improved to 43.6% vs. 20.3% in Q2 2024.
- Contract manufacturing highlights: Cintas reorders accelerating, iRhythm partnership for Zio® heart monitors, and STADA collaboration for 9 new digestive enzyme products.
- Consumer products expansion: Silly George's 75 Lash and Focus Packs launched in Q2, with 5 new lip gloss shades and hydrogel under-eye patches set for Q3/Q4.
- Key partnerships: STADA provided $1 million non-dilutive funding, and AbbVie's delayed medical device project remains a long-term opportunity.
- Cash position: $0.73 million as of Q2, with $1.05 million raised post-quarter and $1 million from STADA.

**【CFO Financial Commentary】**
- GAAP net loss narrowed to $670,000 (vs. $890,000 YoY), with EBITDA loss of $530,000 (vs. $760,000 YoY) and adjusted EBITDA of $420,000 (vs. $790,000 YoY).
- Cost of goods increased to $1.63 million (aligned with Silly George acquisition), while SG&A rose 49% YoY to $1.89 million due to marketing and compensation expenses.
- 2025 guidance: $13 million revenue and positive EBITDA, supported by STADA funding and product pipeline.

**【Q&A Highlights】**
- **STADA Partnership**: New enzymes target larger markets (gluten, dairy) vs. histamine sensitivity (3% prevalence). Retail entry via private label with 8-10 months lead time.
- **Manufacturing Capacity**: Texas plant operates at ~20% utilization, with expansion plans for high-margin medical devices.
- **Silly George Performance**: Q2 sales up 95% YoY, with July being the strongest month. Focus Packs drive 18% new sales with higher margins.
- **Tariffs Impact**: Minimal margin impact, but increased domestic interest in hydrogels for private-label contracts.
- **AbbVie Update**: Device launch delayed to Q1 2026, with no orders expected until FDA approval.
- **Recession Preparedness**: High-margin consumer products and contract manufacturing provide resilience, with no immediate dilution plans.

NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript

- **Revenue Surge**: Q1 2025 revenue up 121% YoY to $2.81M, driven by 189% consumer product growth.
- **Gross Margin Recovery**: 42.4% gross margin, back to historical range after Q4 one-time costs.
- **Key Partnerships**: Cintas reorders, AbbVie delay neutral, STADA to launch 3+ new digestive enzyme products 2025.
- **Tariff Resilience**: 35% tariffs manageable; U.S. manufacturing hedge ready if rates spike.
- **Cash Flow Target**: $13M 2025 revenue, cash flow positive, no debt until EBITDA positive Q4 2025.

**【CEO Summary Section】**
- Q1 2025 revenue reached $2.81 million, up 121% YoY, driven by 58% growth in contract manufacturing and 189% surge in consumer products.
- Gross margin normalized to 42.4%, aligning with historical low-mid 40s range, after one-time Q4 write-offs.
- Key partnerships: Cintas reorders Q2, AbbVie's RESONIC launch delayed due to manufacturing, but NEXGEL remains exclusive gel supplier.
- New consumer products: Silver Seal wound/burn kit, Kenkoderm eczema line, and 5 shades of lip gloss launching Q2-Q3.
- Tariffs: 35% rate manageable; U.S.-made gels gaining interest amid China supply chain risks.
- Guidance: $13 million 2025 revenue, cash flow positive, no material impact from AbbVie delay.

**【CFO Financial Commentary】**
- Q1 2025: 
  - Revenue: $2.81M (vs. $1.27M YoY)
  - COGS: $1.62M (vs. $1.1M YoY)
  - Gross Profit: $1.19M (vs. $0.16M YoY)
  - EBITDA: -$0.54M (vs. -$0.84M YoY)
  - Net Loss: -$0.71M (vs. -$0.85M YoY)
- Cash balance: $1.19M as of March 31, 2025.
- Shares outstanding: 7.65M.

**【Q&A Key Takeaways】**
1. **AbbVie Impact**: Minimal baked-in revenue, but potential $900M+ annual opportunity if RESONIC launch in Q1 2026.
2. **Tariff Strategy**: Texas clean room ready for U.S. manufacturing if tariffs exceed 145%; current 35% rate manageable.
3. **Brand Growth**: [Indiscernible] lashes grew 189% Q1, largest month in May; TikTok marketing on hold due to regulatory uncertainty.
4. **Market Expansion**: Health Canada approval for Silver Seal; U.S.-made gels seeing interest amid China tariffs.
5. **Cash Position**: $1.19M cash; no immediate need for debt until EBITDA positive (expected Q4 2025).

NEXGEL (NXGL)-13 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth Record**: 112% YoY full year growth to $8.69M, Q4 2024 at $3.04M (181% YoY)
- **Gross Margin Stability**: 37.2% Q4 margin after Amazon commission reclassification
- **EBITDA Path to Positive**: Q1 2025 adjusted EBITDA improvement, targeting 2025 full year positive
- **Key Growth Drivers**: 
  - Cintas partnership (Silverseal first aid kits)
  - STADA medical device pipeline
  - Silly George beauty product expansion
- **2025 Outlook**: $13M+ revenue, mid-2025 laser hair removal product launch, Q2 2025 AbbVie shipments

**【CEO Summary Section】**
- **Revenue Growth**: Full year 2024 revenue increased 112% YoY to $8.69 million, driven by 100%+ growth in both branded consumer products and contract manufacturing. Q4 2024 revenue was $3.04 million (181% YoY growth).
- **Gross Margin Adjustment**: Q4 2024 gross margin of 37.2% reflects reclassification of Amazon commissions to COGS, providing more stable investor metrics. Amazon commissions average 15% of sales.
- **EBITDA Performance**: Q4 2024 adjusted EBITDA loss of $621,000 included one-time $243,000 inventory write-offs (Silverseal/Turfguard MOQs and obsolete inventory). Excluding write-offs, adjusted EBITDA would have improved by $243,000.
- **Contract Manufacturing Growth**: 2024 partnerships with Cintas and Owens & Minor drove contract manufacturing expansion. Q4 2024 Silverseal shipments to Cintas exceeded expectations, with additional orders booked for Q1/Q2 2025.
- **New Product Pipeline**: 
  - Medagel launching burn/wound kit and moist burn pads in 2025
  - Kenkoderm expanding into eczema relief products (double product portfolio)
  - Silly George introducing 5+ new beauty products (lash gloss, lip masks, under-eye patches)
  - STADA partnership to launch 2+ new medical devices in 2025
- **2025 Outlook**: 
  - Q1 2025 revenue guidance: $2.75 million (seasonally low, +100% YoY)
  - Full year 2025 target: $13 million+ revenue and positive EBITDA
  - R&D focused on high ROI opportunities with controlled cash allocation

**【CFO Financial Commentary】**
- **Revenue Breakdown**: 
  - Q4 2024: $3.04M (181% YoY)
  - FY 2024: $8.69M (112% YoY)
- **Cost Structure**: 
  - Q4 2024 COGS: $1.91M (15% Amazon commissions)
  - FY 2024 COGS: $5.94M (31.6% gross margin)
- **Expenses**: 
  - Q4 2024 SG&A: $1.97M (includes share-based comp, marketing, Amazon fees)
  - FY 2024 SG&A: $6.2M (115% YoY growth)
- **Liquidity**: $1.81M cash balance as of Q4 2024 end
- **Share Count**: 7.65M shares outstanding as of March 24, 2025

**【Q&A Highlights】**
1. **EBITDA Path to Breakeven**: 
   - Q1 2025 adjusted EBITDA expected to improve vs. Q4 2024
   - Q2 2025+ growth from new contracts will drive EBITDA positive
2. **Pipeline Size & Applications**: 
   - 4-5 large pipeline opportunities in development
   - Applications include medical devices, beauty products, laser hair removal solutions
3. **Laser Hair Removal Market**: 
   - Partnership with Innovative Optics targeting >$1B market
   - Product launch mid-2025 with cooling masks and post-procedure care kits
4. **AbbVie Resonic Device**: 
   - Initial shipments Q2 2025
   - AbbVie managing launch strategy, NEXGEL focused on supply chain

NEXGEL (NXGL)-24 Mar 25-2024 Q4 Earnings call transcript

NEXGEL (NXGL)-13 Nov 24-2024 Q3 Earnings call transcript

NEXGEL (NXGL)-14 Aug 24-2024 Q2 Earnings call transcript

Nexgel (NXGL)-13 May 24-2024 Q1 Earnings call transcript

- **Revenue Surge**: 2023 revenue up 100% YoY to $4.1 million, driven by 166% contract manufacturing growth and 52% branded product expansion.
- **European Market Access**: $303,000 invested in MDR compliance, targeting Q2 2024 approval to unlock European medical device sales.
- **AbbVie Partnership**: $176,000 deposit received; Resonic device launch expected late 2024 with Q4 preorder revenue.
- **Kenkoderm Impact**: Acquired brand contributed $392,000 in Q4, with full Q1 contribution of $1.25 million expected.
- **Cash Position**: $3.7 million in cash (including $1 million post-year-end funding), supporting 2024 growth initiatives.
- **Gross Margin Expansion**: Branded products at 20-25% margins, medical device manufacturing targeting 30-40% as automation scales.


**【CEO Summary Section】**
- **Record Revenue Growth**: Full year 2023 revenue reached $4.1 million, up 99.7% YoY, driven by 166% growth in contract manufacturing and 52% in branded products. Q4 revenue was $1.1 million, up 110% YoY.
- **Gross Margin Expansion**: Full year gross margin improved to 15.1% (vs. 12.5% in 2022). Branded products contribute 20-25% margins, while medical device manufacturing margins target 30-40%.
- **European Market Expansion**: $153,000 spent on MDR compliance in Q4, with final inspection scheduled for Q2 2024. Total compliance costs expected to reach $303,000 by Q2.
- **Key Partnerships**: 
  - **AbbVie**: Received $176,000 non-refundable deposit; launch of Resonic device now expected late 2024.
  - **STADA**: Consumer health products launch mid-summer 2024.
  - **Kenkoderm**: Acquired in December, contributed $392,000 in Q4 revenue. Full Q1 contribution of $1.25 million expected.
- **Operational Scaling**: 
  - Pennsylvania facility operating at 9-13% capacity; expansion to double square footage underway.
  - Texas facility adding 3 automated lines to boost efficiency.

**【CFO Financial Commentary】**
- **Profitability**: Full year gross profit $619,000 (15.2% margin). Q4 gross profit $158,000 (14.6% margin).
- **Cost Management**: 
  - COGS up 93.6% YoY to $3.5 million, aligned with revenue growth.
  - SG&A up 23.4% YoY to $4 million, driven by marketing and consulting fees.
  - R&D down 66% YoY to $103,000, reflecting completion of hydrogel studies.
- **Liquidity**: 
  - $2.7 million cash at year-end; $1 million registered direct offering closed post-year-end.
  - Total shares outstanding 6.2 million as of Q1 2024.

**【Q&A Key Highlights】**
- **Cash Flow Outlook**: CEO expects positive cash flow in 2024, citing fast payment terms from large clients like AbbVie.
- **Kenkoderm Synergies**: Cross-promotion with NEXGEL products planned for Q2 after website update. European interest in Kenkoderm noted.
- **Retail Strategy**: Initial focus on high-margin products (SilverSeal, Kenkoderm) to avoid retail markdown risks.
- **510(k) Devices**: Development on hold to prioritize AbbVie and STADA contracts, though cataract drape R&D continues.
- **Amblyopia Patch**: Shift to Amazon distribution to accelerate sales; reorder patterns emerging from doctors.


Actual	-0.52	-0.33	-0.19	-0.22	-0.11	-0.15	-0.12	-0.1	-0.19	-0.14	-0.14	-0.11	-0.11	-0.09	-0.09	-0.08
Forecast	-0.37	-0.15	-0.15	-0.13	-0.15	-0.14	-0.13	-0.12	-0.11	-0.18	-0.14	-0.1	-0.13	-0.1	-0.07	-0.08	-0.09
Surprise	-40.54%	-120.00%	-26.67%	-69.23%	+26.67%	-7.14%	+7.69%	+16.67%	-72.73%	+22.22%	0.00%	-10.00%	+15.38%	+10.00%	-28.57%	0.00%	0.00%

NXGL

NXGL fundamentals

NXGL Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

NXGL

NXGL fundamentals

NXGL Q4 2025 Earnings Preview

Earnings Call

NXGL Earnings Call Summary for Q4/20254:30 PM on Mar 31, 2026

NXGL Earnings Call Summary for Q3/20254:30 PM on Nov 11, 2025

NXGL Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

NXGL Earnings Call Summary for Q1/2025Invalid Date on May 13, 2025

NXGL Earnings Call Summary for Q4/20244:30 PM on Mar 24, 2025

You can ask Aime